Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation

Table 1

Summary of included studies.

Study	Disease	HLA type and patient number	Conditioning regimens	GVHD prophylaxis	Graft source
McCurdy et al.; Blood 2015 [11]	Hematologic malignancies	Haplo	Haplo: Flu 30 mg/m^2 D-6–2; Cy 14.5 mg/kg D-6-5; TBI 200 cGY D-1	Haplo: PTCy 50 mg/kg D3 and D4,; MMF D5–35,; Tac D5–90 or 180	BM
		Historical MRD or MUD cohort	MRD/MUD: Flu 120 mg/m^2; Bu 3.2–6.4 IV mg/kg; ATG	MRD/MUD: CNI + MTX sirolimus; or; CSP with MMF	BM or PBSC
Ciurea et al.; Blood 2015 [6]	AML	MUD	MAC: TBI/Cy	MUD: CNI + MTX; or; MMF	PBSC > BM
		Haplo	TBI/Flu; Bu/Cy; Mel/Thiotepa/Flu; Bu/Flu; Bu/Flu/ATG; Bu/Thiotepa/Flu; NMA: Flu/Cy/TBI	Haplo: PTCy 50 mg/kg D3 and D4, MMF, and CNI	BM > PBSC
Bashey et al.; BBMT [7]	Hematologic malignancies	MRD; MUD	MRD or MUD: Bu/Cy	MRD or MUD: Tac + MTX ATG alemtuzumab	PBSC ≫ BM
		Haplo	Flu/Bu
			Flu/Bu/Cy; Flu/Mel; Etop/TBI
			Flu/Cy; Flu/Cy/TBI; Cy/TBI; Mel/TBI; Flu/TBI; Bu/Cy/Etop; NMA haplo: Flu/Cy/TBI; MAC haplo: Flu/Bu/Cy; Flu/TBI	Haplo: PTCy 50 mg/kg D3 and D4, MMF, and CNI	NMA haplo: BM ≫ PBSC; MAC haplo: PBSC only
Raiola et al.; BBMT 2014 [3]	Hematologic malignancies	MRD; MUD; mmUD; UCB; Haplo	MAC: Thio/Bu/Flu; Bu/Cy; Flu/TBI; Cy/TBI; RIC: Flu/Cy/TBI; Thio/Cy Mel	MRD: CSP + mini-MTX; MUD: CSP + mini-MTX + ATG; UCB: CSP + MMF + ATG; Haplo: PTCy 50 mg/kg D3 and D4 + CSP + MMF	BM; PBSC; UCB
Bashey et al.; JCO 2013 [5]	Hematologic malignancies	MRD; MUD	RIC or MAC	Standard regimens	PBSC or BM
		Haplo	NMA haplo: Flu 30 mg/m^2 D-6–2; Cy 14.5 mg/kg D-6-5; TBI 200 cGY D-1; or	Haplo: PTCy 50 mg/kg D3 and D4, MMF D5–35, and Tac D5–180	BM for NMA
			MAC haplo: Flu 25 mg/m^2 D-6–2,; Bu 110–130 mg/m^2 IV; D-7–4,; Cy 14.5 mg/kg D-3-2		PBSC for MAC
Di Stasi et al.; BBMT 2014 [4]	AML or MDS	MRD; MUD	MRD/MUD: Flu 120–160 mg/m^2 in 4 daily doses; Mel 140 mg/m^2 or 100 mg/m^2	MRD: Tac + mini-MTX; MUD: Tac + mini-MTX + ATG	BM or PBSC
		Haplo	Haplo: above + thiotepa 5–10 mg/kg	Haplo: PTCy 50 mg/kg D3 and D4,; MMF D5–100,; Tac D5–180	BM or PBSC
Kanakry et al.; BBMT 2013 [10]	Peripheral T-cell lymphoma	MRD	Bu/Cy	MRD: CSP; or; PTCy 50 mg/kg D3 and D4; MMF Tac
		Haplo	Cy/TBI; Flu/TBI; Bu/Flu; Flu/Cy/TBI; Fly/Cy/TBI; Bu/Cy; Cy/TBI	Haplo: PTCy 50 mg/kg D3 and D4,; MMF, Tac, or CSP	BM (1 PBSC)
Burroughs et al.; BBMT 2008 [2]	Hodgkin lymphoma	MRD; MUD	MRD/MUD: TBI 2 Gy; TBI 2 Gy + Flu 30 mg/m^2 days 4–2	MRD/MUD: MMF; or; CNI	PBSC
		Haplo	Haplo: Flu 30 mg/m^2 D-6–2; Cy 14.5 mg/kg D-6-5; TBI 200 cGY D-1	Haplo: PTCy 50 mg/kg D3 (D4),; MMF D4 or 5–35,; Tac D4, or 5–180	BM

HLA: human leukocyte antigen; GVHD: graft-versus-host disease; haplo: HLA-haploidentical; : number; MRD: HLA-matched related donor; MUD: HLA-matched unrelated donor; Flu: fludarabine; D: day; Cy: cyclophosphamide; TBI: total body irradiation; Bu: busulfan; ATG: antithymocyte globulin; PTCy: posttransplantation cyclophosphamide; MMF: mycophenolate mofetil; Tac: tacrolimus; CNI: calcineurin inhibitor; MTX: methotrexate; CSP: cyclosporine; BM: bone marrow; PBSC: peripheral blood stem cells; AML: acute myelogenous leukemia; MAC: myeloablative conditioning; Mel: melphalan; BBMT: biology of blood and marrow transplantation; Etop: etoposide; NMA: nonmyeloablative; mmUD: HLA-mismatched unrelated donor; UCB: umbilical cord blood; JCO: Journal of Clinical Oncology; MDS: myelodysplastic syndrome.
Armand et al. [12], a disease risk index for patients undergoing allogeneic stem cell transplantation, July 2012; Blood: 120 (4) 905–913.